Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader alongside details of the selection of a follow-up prospect and a $750 ...

--Sanofi today announced it has awarded over $1 million in grants through its inaugural Healthy Futures Solution Fund to support local nonprofits across Massachusetts that are advancing community ...

Novavax’s partnership with Sanofi allows the pharma giant to explore potential combinations of assets from both companies, and it’s a blueprint for the kinds of alliances the vaccine developer ...

The US Food and Drug Administration(FDA) has granted Fast Track designation to two non-mRNA combination vaccine candidates put forward by Sanofi.

American depositary receipts of Adagene rose 15% in premarket trading following an investment from Sanofi. ADRs were trading around $2.24. The stock is down 2% on the year. Sanofi agreed to invest ...

Sanofi will advance Kymera's KT-485 into clinical trials while discontinuing KT-474, offering significant collaboration milestones.

Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Sanofi, which is collaborating with Kymera on the development of IRAK4 degraders outside of the oncology and immuno-oncology fields, is progressing the IRAK4 program through clinical development.

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US, saying it intends to spend "at least $20 billion" there by the ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another. The agreement with Gilead ...